Elsbernd Brian's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Sep 5, 2025
- Accession no.
- 0001161697-25-000318
- Filed
- Sep 5, 2025
- Trade date
- Sep 3-4, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $987.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Elsbernd BrianCIK 0001763511 | Officer (Chief Compliance/Legal Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2025 | Common Stock, par value $0.001 per share | MOption exerciseAcquired | +20,000 | $2.24 | +$44,800 | 208,564 | Direct | |
| Sep 3, 2025 | Common Stock, par value $0.001 per share | SSaleDisposed | −20,000 | $20.08F2 | −$401,600 | 188,564 | Direct | |
| Sep 4, 2025 | Common Stock, par value $0.001 per share | MOption exerciseAcquired | +30,000 | $2.24 | +$67,200 | 218,564 | Direct | |
| Sep 4, 2025 | Common Stock, par value $0.001 per share | SSaleDisposed | −30,000 | $19.52F3 | −$585,600 | 188,564 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2025 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 989,084 | Direct | |
| Sep 4, 2025 | Common Stock | MOption exerciseDisposed | −30,000 | $0.00 | $0 | 959,084 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents a weighted average price for the shares sold. Shares were sold in a range from $20.035 to $20.13 per share.
Referenced by the price of 1 transaction in Table I.
- F3
Represents a weighted average price for the shares sold. Shares were sold in a range from $19.325 to $19.73 per share.
Referenced by the price of 1 transaction in Table I.